Tag: pancreatic neuroendocrine tumors
Pancreatic Neuroendocrine Tumors: A Rare Cancer
From your next door neighbor to Steve Jobs, co-founder of Apple who just announced that he is stepping down as CEO of the company, pancreatic neuroendocrine tumors (pNETs) affect less than 1 person in 100,000 in the United States. This rare cancer is often…
READ MORE
Breaking News: Pancreatic NET Cancer Patient Steve Jobs Steps Down as CEO of Apple
On August 24, 2011, Steve Jobs, CEO of Apple, announced that he was stepping down from his position. In his letter to the Apple Board of Directors and the Apple Community, Mr. Jobs wrote, “I have always said if there ever came a day when I could no longer meet…
READ MORE
Phase II Clinical Trial Recruiting Carcinoid and Related Neuroendocrine Tumor Patients
Participants are being recruited for a Phase II clinical study of capecitabine and temozolomide (CAPTEM) for neuroendocrine cancer patients with progressive, differentiated, metastatic neuroendocrine tumors (NETs). Patients with carcinoid,…
READ MORE
Breaking News: FDA Approves Pfizer’s Sutent for Pancreatic NET Cancer Patients
The US Food and Drug Administration today announced approval of Pfizer’s Sutent (sunitinib) for advanced pancreatic neuroendocrine tumor cancer patients with tumors that cannot be removed by surgery or that have spread (metastasized) to …
READ MORE
Breaking News: FDA Approves Pfizer’s Sutent for Pancreatic NET Cancer Patients
The US Food and Drug Administration today announced approval of Pfizer’s Sutent (sunitinib) for advanced pancreatic neuroendocrine tumor cancer patients with tumors that cannot be removed by surgery or that have spread (metastasized) to …
READ MORE
Breaking News: FDA Approves Treatment for pNET Patients
For the first time in nearly three decades, there is a new treatment for pancreatic neuroendocrine tumor patients! The Food and Drug Administration (FDA) today announced its approval of Afinitor© for pNET patients. This is a milestone for the carcinoid/NET…
READ MORE
Carcinoid Cancer Foundation to Speak on Behalf of NET Cancer Patients at April 12, 2011 FDA Oncologic Drugs Advisory Committee Meeting
Grace Goldstein, Chief Operating Officer of the Carcinoid Cancer Foundation, will speak at the Open Public Hearing segment during the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee Meeting on April 12, 2011 in Silver …
READ MORE
Neuroendocrine Tumors Featured on Healthy Body, Healthy Mind Television Series
For a comprehensive overview of neuroendocrine tumors, watch this fascinating video on the Healthy Body, Healthy Mind television series. Every episode on the health and wellness TV series focuses on the stories of real people; people who are working…
READ MORE
Carcinoid Cancer Foundation Thanks Steve Jobs for Bringing about Greater Awareness of Neuroendocrine Cancers
Since the announcement was made earlier this month that Apple’s CEO Steve Jobs would be taking a medical leave of absence there has been significant media coverage about pancreatic neuroendocrine tumors, NET cancer, and carcinoid. Although…
READ MORE
Steve Jobs to Take New Medical Leave from Apple
Steve Jobs, CEO and co-founder of Apple and the most well-known member of the carcinoid and neuroendocrine tumor community, is taking a new medical leave of absence. This announcement was reported today, January 17, 2011, by The New York Times, a year…
READ MORE
